CAR-T Clinical Trial Registry in China: How to Verify Trial Status, Recruitment, and International Access
There is no single official database called the "China CAR-T trial registry." CAR-T trials in China are registered across three different platforms, and each platform covers a different type of research. Checking only one platform is an incomplete verification. More importantly: being registered is not the same as being approved, and being approved is not the same as being eligible. This page explains how to verify a trial's status, and where the three concepts diverge.
Quick Answer
CAR-T clinical trial registration information in China is distributed across three official platforms, each covering a different type of research: the CDE Drug Clinical Trial Registration and Information Disclosure Platform (chinadrugtrials.org.cn, registration numbers CTR + 8 digits) covers drug trials aimed at marketing approval; the Chinese Clinical Trial Registry (ChiCTR, chictr.org.cn, registration numbers ChiCTR + digits) covers many investigator-initiated trials, including early or exploratory CAR-T studies; and ClinicalTrials.gov (registration numbers NCT + 8 digits) covers international multi-center trials and Chinese teams that register internationally. Verifying a CAR-T trial in China requires checking at least CDE and ChiCTR, because China's cell therapy research operates on a dual-track system — registration trials at CDE, investigator-initiated research at ChiCTR. A registration number is the trial's identity; a trial that cannot produce one cannot be verified. But being registered only means the trial is being conducted in a regulated way — it does not prove efficacy, and it does not mean you are eligible.
"If a trial is listed in a registry, it must be approved and I can join it." — Two separate errors. Registration is not approval. A ClinicalTrials.gov record can explicitly state that the sponsor has not obtained NMPA clinical trial approval or clinical technology filing permission to conduct the trial in mainland China. And even an approved, recruiting trial has inclusion and exclusion criteria — a single exclusion criterion can make you ineligible even if everything else fits. Registration, approval, and eligibility are three different gates.
Who This Page Is NOT For
This page is not a tool to determine your eligibility for any trial, and it is not an endorsement of any specific CAR-T product or trial. It is for patients, families, and referring physicians who want to understand how to verify the status of a Chinese CAR-T trial before making any plans. Only the trial team, with the full protocol, can determine eligibility — and only the Chinese regulatory authorities can confirm whether a trial is approved to run in China.
The Three Platforms — and What Each One Covers
China has no single registry organized by treatment technology. Trials are registered by research type, not by drug class. CAR-T trials therefore appear on different platforms depending on their nature.
| Platform | Registration number format | Covers | Can tell you | Cannot tell you |
|---|---|---|---|---|
| CDE Drug Clinical Trial Registration and Information Disclosure Platform (chinadrugtrials.org.cn) | CTR + 8 digits | Drug trials aimed at marketing approval | Trial status (recruiting / not yet recruiting / completed), indication, drug name, participating sites, principal investigator | Does not include investigator-initiated trials; does not guarantee final marketing approval |
| Chinese Clinical Trial Registry (ChiCTR, chictr.org.cn) | ChiCTR + digits | Investigator-initiated trials, observational studies, some registration trials | Registered title, study type, ethics approval number, principal investigator contact, execution dates | Does not distinguish whether the study is aimed at marketing approval; does not guarantee recruiting status |
| ClinicalTrials.gov | NCT + 8 digits | International multi-center trials, Chinese teams registering internationally | Standardized study locations, contacts, eligibility criteria, study status | Registration does not mean Chinese regulatory approval; some records explicitly state they are for global academic information only |
A Real Warning Case: When a Registry Record Does Not Mean Approval
ClinicalTrials.gov contains a record for a DLL3 CAR-T therapy targeting brain tumors (NCT07180927). The record itself states plainly:
Why this matters: The existence of this record does not mean the trial is approved to run in China. A registry entry is a disclosure, not an authorization. If you are considering a Chinese CAR-T trial, the registry record is a starting point — not a confirmation. Ask the trial team for the CDE registration number (CTR) or the ChiCTR number, and verify it on the corresponding platform.
How to Verify a Specific CAR-T Trial: Five Steps
Get the registration number
If the only thing you have is a trial name or drug name, and no registration number, the trial cannot be verified. A legitimate trial has a unique registration number (CTR, ChiCTR, or NCT).
Match the prefix to the platform
CTR → CDE platform. ChiCTR → ChiCTR. NCT → ClinicalTrials.gov. Using the wrong platform for a given prefix will waste your time.
Check the key fields for consistency
At minimum, check: does the indication match your cancer type? Does the status say "recruiting" (not "not yet recruiting" or "completed")? Is the participating site the hospital you plan to attend? Is the principal investigator at that hospital?
Cross-check on a second platform
If the registration number is NCT-based, also check ChiCTR or CDE for a corresponding Chinese record. A CAR-T drug trial lawfully conducted in China should generally have a corresponding CTR registration on CDE.
Contact the study team directly to confirm current recruitment
Registry information can lag. A "recruiting" status on CDE may already be out of date. The most reliable way is to contact the study team through the contact details on the registry page and ask: Is this trial currently recruiting? Does my situation meet the preliminary screening criteria?
Three Concepts That Must Not Be Confused
| Concept | What it means | Common misreading |
|---|---|---|
| Registered | The trial has been registered on one or more public registries, and the information is publicly searchable | "Registered means it is lawful and effective" |
| Approved | The trial has obtained NMPA or ethics committee approval to be conducted at specific institutions | "A ClinicalTrials.gov record means it is approved in China" |
| Eligible | Your cancer type, stage, prior treatment history, performance status, and organ function meet the trial's inclusion criteria and do not trigger any exclusion criterion | "If it is recruiting, I can join" |
A real example from a ChiCTR registration illustrates why the distinction matters. One registered study (ChiCTR2500098577) is described as an observational, retrospective study on autologous stem cell transplantation followed by CAR-T for relapsed/refractory non-Hodgkin lymphoma, with a principal investigator at a specific hospital. "Being enrolled" in a retrospective observational study is not the same as "receiving CAR-T treatment" in a prospective interventional trial. If what you are looking for is an opportunity to receive CAR-T treatment, you need to distinguish between a retrospective data analysis and a prospective trial that is actively recruiting patients.
For Patients Outside China: Two Extra Checks
1. Does the trial accept international patients?
Many Chinese CAR-T trial eligibility criteria do not explicitly exclude foreign nationals, but in practice there may be visa, language, and follow-up considerations. Some hospitals publicly state that they serve international patients — for example, the Jiahui International Cell Therapy Centre has listed patients from Singapore, Hong Kong, Russia, Hungary, New Zealand, India, Pakistan, and the Maldives.
But this is a hospital-level service statement, not a registry field. You need to contact the center directly to confirm whether the specific trial is open to international patients.
2. Is this a clinical trial or commercial treatment?
CAR-T in a clinical trial is usually free (or funded by the sponsor), but entry criteria are strict. Commercial CAR-T treatment (approved products such as Yescarta, Kymriah, or Chinese domestic products) requires payment and can be very expensive. Reported figures put Chinese CAR-T treatment at roughly US$150,000–230,000, compared with US$550,000–850,000 in the United States.
Those figures refer to commercial treatment, not clinical trials. Do not confuse the two.
Questions to Ask Before Any Decision
These questions are educational. They are not an assessment of your case. Review the answers with the trial team and your licensed oncologist.
What is the registration number of this trial?
CTR, ChiCTR, or NCT — and on which platform can I verify it myself?
Is this a registration trial aimed at marketing approval, or an investigator-initiated study?
The two have different regulatory status, different oversight, and different implications for what the results can support.
Is the current status "recruiting," and when was that status last updated?
Registry information can lag. Ask the study team to confirm the current status directly.
Do my cancer type, stage, prior treatment lines, and performance status meet the inclusion criteria?
Ask the study team to review each criterion with you. A single exclusion criterion can make you ineligible.
Does this trial accept non-Chinese patients? If so, what visa and follow-up arrangements are required?
Ask the center directly. Registry records generally do not answer this question.
Who covers the cost of the trial, and what happens if I experience a serious adverse event?
Ask for the cost structure and the adverse event management plan in writing, before you commit.
Can I discuss this trial with my own oncologist before deciding?
Your home oncologist can help you evaluate the trial in the context of your full clinical situation.
Continue Your Research
Related reference pages on Chinese medical documents and CAR-T treatment.
What Do the Terms in a Chinese CAR-T Treatment Record Mean?
Product names, cell types, complications, and follow-up terms.
CAR-T Remission Rates: How to Read the Numbers Before You Travel
Published real-world ranges and what ECOG, prior lines, and disease burden mean for your expected outcome.
Why Your Oncologist Might Not Refer You to China
Seven scenarios where the decision to travel should pause — and what to verify before committing.
Frequently Asked Questions
Is there a single official "China CAR-T trial registry"?
No. China has no registry organized by treatment technology. CAR-T trials are registered by research type, across three platforms: CDE (drug trials aimed at marketing approval), ChiCTR (investigator-initiated and observational studies), and ClinicalTrials.gov (international registrations). Verifying a Chinese CAR-T trial requires cross-checking at least CDE and ChiCTR.
If a trial is registered on ClinicalTrials.gov, does that mean it is approved in China?
No. Registration on ClinicalTrials.gov is a disclosure, not an authorization. Some records explicitly state that the sponsor has not obtained NMPA clinical trial approval or clinical technology filing permission to conduct the trial in mainland China. If you are considering a Chinese CAR-T trial, ask for the CDE registration number (CTR) or the ChiCTR number, and verify it on the corresponding platform.
If a trial is "recruiting," can I join?
Not necessarily. "Recruiting" means the trial is currently enrolling, but you must still meet all inclusion criteria and none of the exclusion criteria. A single exclusion criterion can make you ineligible even if everything else fits. Eligibility is determined by the study team, not by the registry status alone.
What is the difference between a registration trial and an investigator-initiated trial (IIT)?
A registration trial is designed to generate data for marketing approval — it is typically sponsored by a company, conducted under a formal protocol, and registered on CDE. An investigator-initiated trial (IIT) is designed and led by a clinician or research group, often to explore a new approach or generate early evidence. IITs are frequently registered on ChiCTR. The two have different regulatory status, different oversight, and different implications for what the results can support.
What does a ChiCTR registration number tell me?
It tells you that the study has been registered on the Chinese Clinical Trial Registry, which usually means it has an ethics approval number, a stated study type (interventional or observational), a principal investigator, and execution dates. It does not tell you whether the study is recruiting, whether it is aimed at marketing approval, or whether it is suitable for your situation. You need to check the specific record and contact the study team.
How can I tell whether a trial is a clinical trial or a commercial treatment?
A clinical trial has a registration number, a protocol, inclusion and exclusion criteria, and a study team. Commercial treatment involves an approved product, a prescription, and payment. The two are different pathways. Reported figures for commercial CAR-T treatment in China (roughly US$150,000–230,000) refer to commercial treatment, not clinical trials. Do not confuse the two when comparing options.
Where can I find the full list of Chinese medical document reference pages?
This page is part of a series of question-based reference pages on Chinese medical documents. Related pages cover pathology certainty terms, drug-name matching, high-risk mistranslation terms, discharge summaries, laboratory reports, CAR-T records, imaging reports, clinical trial documents, prescription units, and molecular reports. You can find the full list on the Evidence Hub.
Sources & References
- 药物临床试验登记与信息公示平台. 试验公示和查询. chinadrugtrials.org.cn ↗
- 中国临床试验注册中心. ChiCTR2500098577: 自体干细胞移植序贯CAR-T治疗在复发难治性非霍奇金淋巴瘤中的应用. chictr.org.cn ↗
- 南京天印山医院. 临床试验知多少 | 受试者如何找到适合自己的临床试验项目？2024-12-10. tysih.com ↗
- 微信公众平台. CAR-T细胞治疗--如何查询CAR-T临床试验（官方平台）. 2025-07-30.
- 微信公众平台. 怎么自己查临床试验？三个官方渠道手把手. 2026-09-28.
- ClinicalTrials.gov. NCT07180927: DLL3 CAR-T Therapy Targeting Brain Tumors. 2026-08-31. clinicaltrials.gov ↗
- BioSpectrum Asia. Jiahui launches International Cell Therapy Centre to expand global access to CAR-T treatment. 2026-10-28. biospectrumasia.com ↗
- Becker's Oncology. China becoming CAR-T destination for US patients: WSJ. 2026-09-07. beckersoncology.com ↗
- 中国临床试验注册中心. ChiCTR2500115819: 基于GLIM诊断的接受CART细胞治疗血液肿瘤患者的营养评定与临床结局的相关性研究. chictr.org.cn ↗